2nd Batch of Experimental Gilead COVID19 Drug Arrives in Wuhan


    A second batch of Gilead Sciences Inc.’s experimental antiviral drug remdesivir has arrived in Wuhan, where it will be tested on patients infected with the Covid-19 coronavirus that has killed more than 1,500 people.

    The drug was transported from the U.S. to China by FedEx to be distributed to hospitals in Wuhan, the epicenter of the virus, for two ongoing clinical trials on a combined 760 patients.

    It is not known how many doses of the drug were shipped, but they follow some 3,400 doses of the drug and 900 placebo doses that reached Wuhan’s Jinyintan hospital last week as part of Phase 3 trials, which began on Feb. 6.

    More at caixinglobal.com


    Please enter your comment!
    Please enter your name here

    This site uses Akismet to reduce spam. Learn how your comment data is processed.